Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

MB-CART20.1 Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03893019
Recruitment Status : Recruiting
First Posted : March 27, 2019
Last Update Posted : September 21, 2021
Sponsor:
Collaborator:
DLR German Aerospace Center
Information provided by (Responsible Party):
Miltenyi Biomedicine GmbH

Brief Summary:
This is a phase l multi-centric, single arm, prospective, open, dose-escalation study in patients with unresectable stage III oder IV melanoma. The trial will include 15 adult patients. The trial is a classic 3+3 design with 1 Log dose increments and maximum 3 dose levels of the intravenously administered MB-CART20.1.

Condition or disease Intervention/treatment Phase
Melanoma (Skin) Biological: MB-CART20.1 Early Phase 1

Detailed Description:
This Phase I trial will be the first trial with CD20 CAR transduced T cells in Europe targeting melanoma. The rationale for the trial is based on the finding that melanoma cancer sustaining cells express CD20 and that targeting CD20+ cells in preclinical model has a strong antitumor effect.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter Phase I Trial of MB-CART20.1 for the Treatment of Patients With Metastatic Melanoma
Actual Study Start Date : March 8, 2019
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : July 2022

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: Dose Level 1: 1x10e5 MB-CART20.1 cells
3+3 patients will be treated with 1x10e5 MB-CART20.1 cells per kg body weight administered intravenously
Biological: MB-CART20.1
MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD20.positive tumor cells
Other Names:
  • CD20-targeting CAR T cells
  • anti-CD20 CAR T cells

Experimental: Dose Level 2: 1x10e6 MB-CART20.1 cells
3+3 patients will be treated with 1x10e6 MB-CART20.1 cells per kg body weight administered intravenously
Biological: MB-CART20.1
MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD20.positive tumor cells
Other Names:
  • CD20-targeting CAR T cells
  • anti-CD20 CAR T cells

Experimental: Dose Level 3: 1x10e7 MB-CART20.1 cells
3+3 patients will be treated with 1x10e7 MB-CART20.1 cells per kg body weight administered intravenously
Biological: MB-CART20.1
MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD20.positive tumor cells
Other Names:
  • CD20-targeting CAR T cells
  • anti-CD20 CAR T cells




Primary Outcome Measures :
  1. Determination of MTD [ Time Frame: Week 4 after infusion of MB-CART20.1 ]
    MTD is defined as the highest dose level at which < 33% of patients experience dose limiting toxicity (DLT)

  2. Safety and Toxicity Assessment per Adverse Event reporting classified according to CTCAE V5.0 [ Time Frame: until day 28 after infusion of MB-CART20.1 ]
    per Adverse Event reporting classified according to CTCAE V5.0


Secondary Outcome Measures :
  1. Clinical Response [ Time Frame: 1 year after infusion of MB-CART20.1 ]
    Number of patients with either Complete Response, Partial Response, Stable Disease or Progressive Disease using RECIST 1.1

  2. Frequency of B-cell aplasia [ Time Frame: 1 year after infusion of MB-CART20.1 ]
    Circulating B cell numbers in the peripheral blood will be assessed by Flow cytometry

  3. Phenotype and Persistence of infused MB-CART20.1 [ Time Frame: 1 year after infusion of MB-CART20.1 ]
    Blood samples for determination of persistence/phenotyping of infused MB-CART20.1 will be analysed.

  4. Presence and phenotype of MB-CART20.1 and B cells in biopsies [ Time Frame: Screening, 8 weeks after infusion of MB-CART20.1 ]
    Tumor biopsies for determination of persistence/phenotyping of infused MB-CART20.1 will be analysed

  5. Number of CD20+ tumor cells [ Time Frame: Screening, 8 weeks after infusion of MB-CART20.1 ]
    Tumor biopsies for determination of number of CD20+ tumor cells

  6. Persistence of T-cell expansion for each dose group [ Time Frame: Day 0 and week 12 ]
    Blood samples for determination MB-CART20.1 levels (transgene copies / genomic DNA)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Male or female patients with

  • Histologically confirmed unresectable stage III or stage IV melanoma
  • Willingness to provide a tumor biopsy between the screening visit and prior to administration of the IMP and eight weeks after treatment
  • Progressive disease despite treatment with indicated standard therapies. Time window for decision about progressive disease is to be made depending on the treatment regimen chosen.
  • Measurable lesions according to RECIST1.1
  • ECOG (Eastern cooperative oncology group) performance status of 0-2
  • Negative serological hepatitis B (HBV) test defined as negative tests for HBsAg and HBcAb, unless serology is positive due to recent IVIG therapy, HBcAb positivity will be allowed if HbsAb is present, negative testing of HCVAb, negative human immunodeficiency virus (HIV) 1/2 test within 6 weeks prior to enrollment.
  • Estimated life expectancy of more than 6 months
  • At least 18 years of age
  • WBC ≥ 2500/µL
  • ANC ≥ 1000/µL
  • Platelets ≥ 75 x 103/µL
  • Hemoglobin ≥ 9 g/dL
  • AST ≤ 3 x upper limit of normal (ULN) for patients without liver metastasis
  • AST < 5 x ULN for patients with liver metastasis
  • Total Bilirubin ≤ 2 x ULN
  • patients with Gilbert's Syndrome increase of indirect bilirubin < 6mg/dL
  • No childbearing potential (i.e. postmenopausal, absence of menstrual bleeding for at least 1 year, hysterectomy, bilateral ovariectomy or tubal section/ligation) or negative pregnancy test at screening and before chemotherapy in women with childbearing potential. Sexually active female patients of childbearing potential should use one of the following highly effective methods of contraception (Pearl index < 1%): hormonal contraceptives (oral, injected, implanted, transdermal), intrauterine devices or systems (e.g. hormonal and non-hormonal IUD), or vasectomized sexual partner for at least 1 month before the trial start, during the course of the trial and in the 6 months following dosing. Sexual abstinence is restricted to true abstinence ( in line with the preferred and usual lifestyle of the subject).
  • male patients, unless surgically sterile, must be using two acceptable methods for contraception (e.g. spermicide and condom) during the trial and refrain from fathering a child throughout the trial and for up to 12 months after dosing.
  • Signed and dated informed consent before conduct of any trial-specific procedure.

Exclusion Criteria:

  • Any evidence of brain metastases
  • CNS (central nervous system) disorders and previous strokes, if clinically relevant
  • Patients with epilepsy
  • Clinically relevant autoimmune disorders or history of clinically relevant autoimmune disorders
  • Patients with T-cell lymphoma
  • Treatment with anti-CD20 antibodies or checkpoint blockade inhibitors within 6 weeks before leukapheresis
  • Chemotherapy within 6 weeks prior to leukapheresis
  • History of primary immunodeficiency
  • Creatinine clearance < 50 ml/min calculated according to the modified formula of Cockcroft and Gault
  • concurrent systemic radiotherapy
  • Use of systemic corticosteroids and immunosuppressive medication except prednisone ≤ 10 mg QD or equivalent
  • Patients with severe cardiac disease (e.g. NYHA Functional Class III or IV, myocardial infarction within 6 months before inclusion, ventricular tachyarrhythmia requiring ongoing treatment, unstable angina pectoris)
  • Other investigational treatment within 4 weeks before MB-CART20.1 infusion
  • Hypersensitivity against any drug or its ingredients/impurities that is scheduled or likely to be given during trial participation, e.g. as part of the mandatory lymphodepletion protocol, pre-medication for infusion, rescue medication/salvage therapies for treatment related toxicities
  • Patients in which such medication (likely to be given during trial participation) is contraindicated for other reasons than hypersensitivity, e.g. live vaccines and fludarabine.
  • Severe pulmonary disease (DLCO and/or FEV1 < 65%, dyspnoea at rest)
  • Active systemic fungal, viral or bacterial infection
  • Pregnant or lactating women
  • Patient's lack of accountability, inability to appreciate the nature, meaning and consequence of the trial and to formulate his/her own wishes correspondingly
  • Patients who have a relationship of dependence or employer employee relationship to the sponsor or the investigator
  • Committal to an institution on judicial or official order

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03893019


Contacts
Layout table for location contacts
Contact: Christine Schubert +49 2204 8306 6564 christines@miltenyibiotec.de
Contact: Sandra Karitzky, Dr. +49 2204 8306 6560 sandrak@miltenyibiotec.de

Locations
Layout table for location information
Germany
University Hospital of Cologne - Clinic for Internal Medicine I Recruiting
Cologne, NRW, Germany, 50937
Contact: Peter Borchmann, Prof. Dr.    +49 221 478 ext 88159    peter.borchmann@uk-koeln.de   
Contact: Udo Holtick, PD Dr.    +49 221 478 4407    udo.holtick@uk-koeln.de   
Sponsors and Collaborators
Miltenyi Biomedicine GmbH
DLR German Aerospace Center
Investigators
Layout table for investigator information
Principal Investigator: Peter Borchmann, Prof. Universitätsklinikum Köln
Layout table for additonal information
Responsible Party: Miltenyi Biomedicine GmbH
ClinicalTrials.gov Identifier: NCT03893019    
Other Study ID Numbers: M-2015-307
First Posted: March 27, 2019    Key Record Dates
Last Update Posted: September 21, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas